Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops

Core Viewpoint - Ardelyx Inc. reported a breakeven performance for Q4 2025, with sales of $125.22 million, surpassing the consensus estimate of $118.13 million [1] Revenue Performance - IBSRELA (tenapanor) revenue grew 73% in 2025 to $274.2 million, contributing to total revenues of $407.3 million; Q4 revenue for IBSRELA was $86.6 million, up 61% year over year [2] - XPHOZAH (tenapanor) revenue in 2025 was $103.6 million, with Q4 revenue of $27.8 million; expected 2026 revenue for XPHOZAH is projected between $110 million and $120 million [4] Growth Expectations - Ardelyx anticipates full-year 2026 revenue for IBSRELA to be between $410 million and $430 million, indicating at least 50% growth compared to 2025 [2] - The company expects IBSRELA to achieve $1 billion in annual revenue by 2029, with further growth anticipated thereafter [3] Pipeline Developments - Ardelyx plans to submit a Supplemental New Drug Application to the FDA for the CIC indication, pending Phase 3 trial outcomes; enrollment in the ACCEL trial is expected to complete by the end of 2026 [5] - A development program for RDX10531, a next-generation sodium/hydrogen exchanger 3 (NHE3) inhibitor, is underway, with an Investigational New Drug submission planned for the second half of 2026 [6] Technical Analysis - Ardelyx shares are currently trading 17.6% below the 20-day simple moving average (SMA) and just 0.1% below the 100-day SMA, indicating short-term weakness [7] - The stock has increased 17.83% over the past 12 months and is closer to its 52-week highs than lows [7] Analyst Consensus - The stock carries a Buy Rating with an average price target of $12.86; recent analyst actions include maintaining a Buy rating with a target of $17.00 and raising the target to $19.00 [10]